Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fiorella trial in elderly patients with newly diagnosed primary central nervous system lymphoma
MOH_2019-11-10_007479Phase 2Active, not recruiting
- Sponsor
- (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide, procarbazine, methotrexate and rituximab in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP. Started May 2019; status: active, not recruiting.
02
Drugs
lenalidomideprocarbazinemethotrexaterituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on MOH_2019-11-10_007479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-10_007479.